Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PEP-CMV by Immunomic Therapeutics for Anaplastic Astrocytoma: Likelihood of Approval
PEP-CMV is under clinical development by Immunomic Therapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...
Umitrelimorgene autodencel by Immunomic Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
Umitrelimorgene autodencel is under clinical development by Immunomic Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to...
Vaccine for Central Nervous System Cancer by Immunomic Therapeutics for Oligodendroglioma: Likelihood of Approval
Vaccine for Central Nervous System Cancer is under clinical development by Immunomic Therapeutics and currently in Phase I for Oligodendroglioma....
Vaccine for Central Nervous System Cancer by Immunomic Therapeutics for Anaplastic Astrocytoma: Likelihood of Approval
Vaccine for Central Nervous System Cancer is under clinical development by Immunomic Therapeutics and currently in Phase I for Anaplastic...
ITI-1000 by Immunomic Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
ITI-1000 is under clinical development by Immunomic Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...